3.70

3.14% -0.12

Pre-market: 3.82 0.12 +3.24%

Elevation Oncology Inc (ELEV)

Overview News Price History Financials Discussions Forecast

Elevation Oncology Inc stock is currently priced at $3.70, with a 24-hour trading volume of 431.65K. It has seen a -3.14% decreased in the last 24 hours and a -28.43% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $3.71 pivot point. If it approaches the $3.29 support level, significant changes may occur.

Previous Close:

$3.82

Open:

$3.81

24h Volume:

431.65K

Market Cap:

$180.01M

Revenue:

Net Income/Loss:

$-45.70M

P/E Ratio:

-1.0335

EPS:

-3.58

Net Cash Flow:

$-56.18M

1W Performance:

+2.21%

1M Performance:

-28.43%

6M Performance:

+731.27%

1Y Performance:

+6.02%

1D Range:

$3.69

$4.13

52W Range:

$0.363

$5.89

Elevation Oncology Inc Stock (ELEV) Company Profile

Name

Elevation Oncology Inc

Sector

Healthcare (1213)

Industry

Biotechnology (699)

Phone

716 371 1125

Address

888 Seventh Avenue, 12th Floor, New York

Employee

Twitter

Next Earnings Date

Latest SEC Filings

ELEV's Discussions on Twitter

Elevation Oncology Inc Stock (ELEV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-23-21	Initiated	H.C. Wainwright	Buy

Elevation Oncology Inc Stock (ELEV) Latest News

Why Aehr Test Systems Shares Are Trading Lower By 15%; Here Are 20 Stocks Moving Premarket

Benzinga

Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Benzinga

Elevation Oncology Inc Stock (ELEV) Financials Data

Elevation Oncology Inc (ELEV) Net Income 2024

ELEV net income (TTM) was -$45.70 million for the quarter ending December 31, 2023, a +51.93% increase year-over-year.

Elevation Oncology Inc (ELEV) Cash Flow 2024

ELEV recorded a free cash flow (TTM) of -$56.18 million for the quarter ending December 31, 2023, a +34.28% increase year-over-year.

Elevation Oncology Inc (ELEV) Earnings per Share 2024

ELEV earnings per share (TTM) was -$1.47 for the quarter ending December 31, 2023, a +64.06% growth year-over-year.

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.